The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Launched by SAMSUNG MEDICAL CENTER · Feb 18, 2016

Keywords

ClinConnect Summary

The SUKSES-S trial is focused on understanding the genetic makeup of small cell lung cancer, particularly in patients whose cancer has come back after treatment. This study does not involve testing any new medications yet; instead, it aims to gather important information from tissue and blood samples to see if participants might qualify for future drug studies based on their cancer's molecular characteristics. Patients will have their samples analyzed using various methods to identify specific features of their cancer.

To be part of this study, participants need to be at least 20 years old and have a confirmed diagnosis of small cell lung cancer. They should also have received platinum-based chemotherapy as their first treatment. Before joining, patients must provide consent and may need to supply tissue samples from previous treatments or agree to a biopsy. The trial is currently recruiting patients, and all genders are welcome to participate. This study is a valuable opportunity to help researchers learn more about small cell lung cancer and potentially improve future treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of fully informed consent prior to any study specific procedures.
• • 2. Patients must be ≥20 years of age.
• • 3. Histologically or cytologically confirmed Small cell lung cancers
• • 4. ECOG performance status of 0 to 2
• • 5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
• • 6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis
• Exclusion Criteria:
• • 1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer
• • 2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
• • 3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.